Drug safety information: Lumiracoxib - Suspension of UK licences with immediate effect - Further information

---

Dear Healthcare Professional,

Please note that further to the Drug Safety Information and Public Health Link letters of 19 November 2007 (our reference EL(07)A/21), all Lumiracoxib products should be returned from Pharmacy level via suppliers within 5 days of receipt of this letter. This is equivalent to a Class 3 Pharmacy Level recall.

Queries should be addressed to Novartis Pharmaceuticals UK Ltd Medical Information on 01276 698 370

Recipients of this letter are asked to bring this information to the attention of relevant professionals by copy of this letter. Primary care trusts are asked to bring this information to the attention of relevant clinics, General Practitioners and Community Pharmacists by copy of this letter.

Yours faithfully

Graham Matthews
Senior Pharmaceutical Assessor
Defective Medicines Report Centre

MHRA Distribution (further recipients by cascade):

Regional Contacts for NHS Trusts and Provider Units
Chief Pharmacists: England, Scotland, Wales, Northern Ireland
Prison Health Policy Unit (DH)
Medical Supplies Agency (MOD)
Chief Pharmacists: Jersey, Guernsey, Alderney, Sark, Isle of Man, Gibraltar
Special Hospitals
Healthcare Commission for distribution to Independent Health Care Establishments
Primary Care Trusts (England)